The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05633602
Recruitment Status : Recruiting
First Posted : December 1, 2022
Last Update Posted : February 8, 2024
National Cancer Institute (NCI)
Eli Lilly and Company
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
SWOG Cancer Research Network

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 15, 2025
Estimated Study Completion Date : March 15, 2028